FindTrial
Sign In

Evaluation of immunity in the evolution of the severe or mild form of COVID-19

Immune biomarkers in the prognosis of COVID-19

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-62zdkk
Enrollment
Unknown
Registered
2020-07-17
Start date
2020-06-12
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus

Interventions

Blood samples will be collected at D0, D3, D10 and D15 from patients with mild (n=100), moderate (n=50) and severe forms (n=50) of COVID-19 for analysis of circulating biomarkers, phenotypic / functio
Other
D23.101
E01.370.225.625.115.830
D06.472.699.322.576.773
D12.644.276.374.200
D12.644.276.374
D12.776.124.486.485.114.244

Sponsors

Hospital Universitário de Brasília
Lead Sponsor
Fundação Oswaldo Cruz
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: patients of both genders; diagnosed with COVID-19; age over 18

Exclusion criteria

Exclusion criteria: do not fill out the informed consent form; age under 18 years

Design outcomes

Primary

MeasureTime frame
Increase greater than 20%; in circulating cytokines and chemokines; measured in peripheral blood collected at D10 from hospitalized patients—

Secondary

MeasureTime frame
Secondary outcomes are not expected—

Countries

Brazil

Contacts

Public ContactPatricia Kurizky

Universidade de Brasília

patyshu79@gmail.com55 61981148432

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 16, 2026